| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 10/10/2001 | EP1140115A2 Phospholipid complexes of proanthocyanidin a2 as antiatherosclerotic agents |
| 10/10/2001 | EP1140114A2 Pharmaceutical formulations |
| 10/10/2001 | EP1140113A2 Use of bisphosphonates for the prevention and treatment of infectious processes |
| 10/10/2001 | EP1140112A1 Use of etherlysophospholipids as antiinflammatory agents |
| 10/10/2001 | EP1140111A1 Pharmaceutical aerosol formulations containing fluoroalkanes and budesonide |
| 10/10/2001 | EP1140110A2 Clathrates of dehydroepiandrosterone and corresponding pharmaceutical compositions |
| 10/10/2001 | EP1140109A1 Triphasic oral contraceptive |
| 10/10/2001 | EP1140108A1 Method and composition for treatment of female sexual dysfunction |
| 10/10/2001 | EP1140106A1 Treatment of diseases involving cyst formation |
| 10/10/2001 | EP1140105A1 Controlled release galantamine composition |
| 10/10/2001 | EP1140104A1 Methods for increasing cytidine levels in vivo and treating cytidine-dependent human diseases |
| 10/10/2001 | EP1140103A2 Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma |
| 10/10/2001 | EP1140102A2 Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma |
| 10/10/2001 | EP1140101A1 Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma |
| 10/10/2001 | EP1140100A2 Use of (s)-triazines for treating apicomplexan parasitic infections |
| 10/10/2001 | EP1140099A1 Utilisation of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia |
| 10/10/2001 | EP1140098A2 Tricyclic nitrogen heterocycles as pde iv inhibitors |
| 10/10/2001 | EP1140096A1 Utilization of pyrimidine derivatives for preventing and treating cerebral ischaemia |
| 10/10/2001 | EP1140095A1 (2-imidazoline-2-ylamino) quinoxaline derivatives for the treatment of pain |
| 10/10/2001 | EP1140094A1 Use of apomorphine in the manufacture of a medicament for the treatment of organic erectile dysfunction in males |
| 10/10/2001 | EP1140093A2 Compositions having improved delivery of actives |
| 10/10/2001 | EP1140092A2 Method of treating sexual disturbances |
| 10/10/2001 | EP1140091A2 Formulations comprising imiquimod or other immune response modifiers for treating mucosal consitions |
| 10/10/2001 | EP1140090A1 Use of phanquinone for the treatment or prevention of memory impairment |
| 10/10/2001 | EP1140089A1 Liposomic niflumic acid - new transdermal anti-inflammatory medicine |
| 10/10/2001 | EP1140088A1 Controlled/modified release oral methylphenidate formulations |
| 10/10/2001 | EP1140085A1 Azabicycloalkanes as ccr5 modulators |
| 10/10/2001 | EP1140084A1 Novel formulation |
| 10/10/2001 | EP1140083A1 Novel compounds |
| 10/10/2001 | EP1140082A1 Combination of cerivastatin and fibrates |
| 10/10/2001 | EP1140081A2 Improving mental performance by increasing brain insulin sensitivity |
| 10/10/2001 | EP1140080A1 Use of riluzole for treating acoustic traumas |
| 10/10/2001 | EP1140079A1 Assays for ligands for nuclear receptors |
| 10/10/2001 | EP1140078A2 Benzimidazole vascular damaging agents |
| 10/10/2001 | EP1140077A2 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
| 10/10/2001 | EP1140076A1 Use of 5ht3-receptor antagonists for the treatment of chronic fatigue syndrome |
| 10/10/2001 | EP1140075A1 Treatment of retroviral infections with oxyphenbutazone |
| 10/10/2001 | EP1140074A1 Indole and indolizidine derivatives for the treatment of migraine |
| 10/10/2001 | EP1140073A1 Combinations of farnesyl transferase inhibitors and irinotecan or camptothecin for treating cancer |
| 10/10/2001 | EP1140072A1 Compounds and methods |
| 10/10/2001 | EP1140071A1 Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors |
| 10/10/2001 | EP1140070A1 Treatment of conditions with a need for the inhibition of gsk-3 |
| 10/10/2001 | EP1140069A1 COMPOUNDS WHICH AFFECT mRNA STABILITY AND USES THEREFOR |
| 10/10/2001 | EP1140068A1 Doramectin formulations |
| 10/10/2001 | EP1140067A1 Antiviral method using mek inhibitors |
| 10/10/2001 | EP1140066A1 Nitrosated and nitrosylated h2 receptor antagonist compounds, compositions and methods of use |
| 10/10/2001 | EP1140065A1 Use of gamma-tocopherol and its oxidative metabolite llu-alpha in the treatment of disease |
| 10/10/2001 | EP1140064A2 Oral administration of taxoid derivatives |
| 10/10/2001 | EP1140063A1 Method and composition for the maintenance and restitution of gut integrity |
| 10/10/2001 | EP1140062A2 Treatment of asthma with mek inhibitors |
| 10/10/2001 | EP1140061A2 Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
| 10/10/2001 | EP1140060A2 Use of a nitrosourea derivative for prevention or treatment of acute allograft rejection |
| 10/10/2001 | EP1140059A2 Pharmaceutical aerosol formulations containing fluoroalkanes, budesonide and formoterol |
| 10/10/2001 | EP1140058A1 N-formyl hydroxylamine derivatives as antibacterial agents |
| 10/10/2001 | EP1140057A1 Pharmaceutical composition containing metformin, acarbose or glimepiride and optionally poly-(dimethyl)-siloxane |
| 10/10/2001 | EP1140056A2 The utilisation of inhibitors of the sodium hydrogen exchanger for producing a medicament for preventing organ dysfunctions and diseases related to a particular age and for prolonging life |
| 10/10/2001 | EP1140055A1 Use of a 5ht 2a? and 5ht 2a/c? receptor antagonist for preparing medicines for treating snoring and high resistance syndrome of upper anatomical airways |
| 10/10/2001 | EP1140054A2 Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions |
| 10/10/2001 | EP1140053A1 Composition and method for enhancing male fertility and libido |
| 10/10/2001 | EP1140052A2 Sensitizing agents for the treatment of skin lesions |
| 10/10/2001 | EP1140051A2 Use or tertbutylhydroquinone for lowering blood cholesterol and/or blood triglycerides |
| 10/10/2001 | EP1140050A2 A composition useful to treat periodontal disease |
| 10/10/2001 | EP1140049A2 Compositions and methods to inactivate n-type calcium channels |
| 10/10/2001 | EP1140048A2 Methods for treating certain diseases using naaladase inhibitors |
| 10/10/2001 | EP1140047A2 Endocrine therapy for breast cancer: combined treatment with tamoxifen plus alkyl pcdfs |
| 10/10/2001 | EP1140046A1 Use of a mek inhibitor for preventing transplant rejection |
| 10/10/2001 | EP1140045A2 Homer a new target of treating psychiatric disorders |
| 10/10/2001 | EP1140044A2 cGMP PDE 5 INHIBITORS FOR INHALATION IN THE TREATMENT OF SEXUAL DYSFUNCTION |
| 10/10/2001 | EP1140042A1 Utilization of inhibitors of the kqt1 channel in order to produce a medicament for treating diseases which are caused by parasitic helminths and ectoparasites |
| 10/10/2001 | EP1140041A2 Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| 10/10/2001 | EP1140039A1 Transparent transdermal nicotine delivery devices |
| 10/10/2001 | EP1140038A1 Transdermal drug delivery system |
| 10/10/2001 | EP1140037A1 Multiparticulate oral dosage forms |
| 10/10/2001 | EP1140036A2 Novel formulations comprising lipid-regulating agents |
| 10/10/2001 | EP1140035A1 Method for preparing an effervescent granulate comprising iron gluconate, granulate thus obtained and tablets containing the same |
| 10/10/2001 | EP1140034A1 Controlled release formulation of divalproex sodium |
| 10/10/2001 | EP1140033A2 Improved controlled release compositions and method |
| 10/10/2001 | EP1140032A1 A pharmaceutical mixture comprising a profen |
| 10/10/2001 | EP1140031A1 Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient |
| 10/10/2001 | EP1140030A2 Medicament forms having controlled release and containing active substances which easily dissolve in water |
| 10/10/2001 | EP1140028A1 Methods for treating ovarian cancer, poly(phosphoester) compositions, and biodegradable articles for same |
| 10/10/2001 | EP1140027A1 Dosage forms comprising porous particles |
| 10/10/2001 | EP1140026A1 Biodegradble polymer encapsulated serotonin receptor antagonist and method for preparing the same |
| 10/10/2001 | EP1140025A1 Granules for oral administration, process for producing the same, and tablets produced from the granules |
| 10/10/2001 | EP1140024A2 Particles for oral delivery of peptides and proteins |
| 10/10/2001 | EP1140022A2 Method of administering a compound to multi-drug resistant cells |
| 10/10/2001 | EP1140021A1 Improved formulation for topical non-invasive application in vivo |
| 10/10/2001 | EP1140020A1 Large molecule drug delivery system using aerosolized membrane-mimetic amphiphiles |
| 10/10/2001 | EP1140019A1 Aerosol formulations for buccal and pulmonary application |
| 10/10/2001 | EP1140017A1 Water-insoluble drug delivery system |
| 10/10/2001 | EP1140016A1 Composition set and kit for use in intraocular surgery |
| 10/10/2001 | EP1140011A1 Pharmaceutical composition for oral administration designed to prevent misuse at the expense of a third party |
| 10/10/2001 | EP1140010A2 Substrate composition and method of use for sequestration of skin irritants |
| 10/10/2001 | EP1140009A2 Absorbent article composition and method of use for sequestering skin irritants |
| 10/10/2001 | EP1140006A1 Skin protection agents containing a fragment mixture produced from hyaluronic acid by hydrolysis |
| 10/10/2001 | EP1140005A1 Utilization of an extract of a plant of the cecropia genus |
| 10/10/2001 | EP1140003A1 Skin care composition containing cis-9, trans-11 linoleic acid |
| 10/10/2001 | EP1140001A2 Composition for treatment of burns |
| 10/10/2001 | EP1140000A1 Osmetische oder dermatologische zusammensetzub |
| 10/10/2001 | EP1139999A1 Topical compositions including deodorant compositions |